PMID- 29406285
OWN - NLM
STAT- MEDLINE
DCOM- 20180801
LR  - 20180801
IS  - 1878-1667 (Electronic)
IS  - 0147-9571 (Linking)
VI  - 56
DP  - 2018 Feb
TI  - Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and 
      matrix metalloproteinase-9 and improves pathological changes in the lungs and 
      heart of mice infected with influenza A virus.
PG  - 6-13
LID - S0147-9571(17)30095-4 [pii]
LID - 10.1016/j.cimid.2017.11.002 [doi]
AB  - The influenza A virus (IAV)-cytokine-trypsin/matrix metalloproteinase-9 (MMP-9) 
      cycle is one of the important mechanisms of multiple organ failure in severe 
      influenza. Clarithromycin, a macrolide antibiotic, has immune modulatory and 
      anti-inflammatory effects. We analyzed the effects of clarithromycin on the 
      induction of chemokines, cytokines, MMP-9, trypsin, vascular hyper-permeability 
      and inflammatory aggravation in mice with IAV infection. IAV/Puerto 
      Rico/8/34(H1N1) infection increased the levels of monocyte chemoattractant 
      protein-1 (MCP-1) and cytokines in serum, and MMP-9 and trypsin in serum and/or 
      the lungs and heart. Clarithromycin significantly suppressed the induction of 
      serum MCP-1 and MMP-9 and vascular hyperpermeability in these organs in the early 
      phase of infection, but did not suppress the induction of trypsin, IL-6 or IFN-gamma. 
      Histopathological examination showed that clarithromycin tended to reduce 
      inflammatory cell accumulation in the lungs and heart. These results suggest that 
      clarithromycin suppresses infection-related inflammation and reduces vascular 
      hyperpermeability by suppressing the induction of MCP-1 and MMP-9.
CI  - Copyright (c) 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Takahashi, Etsuhisa
AU  - Takahashi E
AD  - Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima 
      University, Kuramoto-cho 3-18-15, Tokushima 770-8503, Japan.
FAU - Indalao, Irene L
AU  - Indalao IL
AD  - Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima 
      University, Kuramoto-cho 3-18-15, Tokushima 770-8503, Japan.
FAU - Sawabuchi, Takako
AU  - Sawabuchi T
AD  - Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima 
      University, Kuramoto-cho 3-18-15, Tokushima 770-8503, Japan.
FAU - Mizuno, Keiko
AU  - Mizuno K
AD  - Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima 
      University, Kuramoto-cho 3-18-15, Tokushima 770-8503, Japan.
FAU - Sakai, Satoko
AU  - Sakai S
AD  - Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima 
      University, Kuramoto-cho 3-18-15, Tokushima 770-8503, Japan.
FAU - Kimoto, Takashi
AU  - Kimoto T
AD  - Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima 
      University, Kuramoto-cho 3-18-15, Tokushima 770-8503, Japan.
FAU - Kim, Hyejin
AU  - Kim H
AD  - Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima 
      University, Kuramoto-cho 3-18-15, Tokushima 770-8503, Japan.
FAU - Kido, Hiroshi
AU  - Kido H
AD  - Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima 
      University, Kuramoto-cho 3-18-15, Tokushima 770-8503, Japan. Electronic address: 
      kido@tokushima-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20171123
PL  - England
TA  - Comp Immunol Microbiol Infect Dis
JT  - Comparative immunology, microbiology and infectious diseases
JID - 7808924
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Chemokine CCL2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Blotting, Western
MH  - Chemokine CCL2/*metabolism
MH  - Clarithromycin/*therapeutic use
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - *Influenza A virus
MH  - Lung/*pathology
MH  - Matrix Metalloproteinase 9/*metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Myocardium/*pathology
MH  - Orthomyxoviridae Infections/*drug therapy/immunology/pathology/virology
OTO - NOTNLM
OT  - BBB
OT  - Clarithromycin
OT  - Evans' blue extravasation
OT  - IAV
OT  - Influenza A virus infection
OT  - MC
OT  - MOF
OT  - Macrolide
OT  - Matrix metalloproteinase-9
OT  - Multiple organ failure
OT  - PID
OT  - PR8
OT  - blood-brain barrier
OT  - influenza A virus
OT  - influenza A/Puerto Rico/8/34(H1N1)
OT  - methyl cellulose
OT  - multiple organ failure
OT  - pfu
OT  - plaque-forming units
OT  - post-infection day
EDAT- 2018/02/07 06:00
MHDA- 2018/08/02 06:00
CRDT- 2018/02/07 06:00
PHST- 2017/04/01 00:00 [received]
PHST- 2017/10/07 00:00 [revised]
PHST- 2017/11/15 00:00 [accepted]
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2018/08/02 06:00 [medline]
AID - S0147-9571(17)30095-4 [pii]
AID - 10.1016/j.cimid.2017.11.002 [doi]
PST - ppublish
SO  - Comp Immunol Microbiol Infect Dis. 2018 Feb;56:6-13. doi: 
      10.1016/j.cimid.2017.11.002. Epub 2017 Nov 23.